%0 Journal Article
%T Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children
%A Zahra Gharibnaseri
%A Abbas Kebriaeezadeh
%A Shekoufeh Nikfar
%A Gholamreza Zamani
%A Akbar Abdollahiasl
%J DARU Journal of Pharmaceutical Sciences
%D 2012
%I BioMed Central
%R 10.1186/2008-2231-20-17
%X Clinical and cost data were collected from medical and cost records preserved at a neurologist office and a referral pharmacy respectively. Based on the new AED which are accessible in Iran, regimens were categorized into eight groups. The first group consisting of conventional AEDs was considered as comparator and the effectiveness of other groups was compared with it. Incremental Cost-effectiveness Ratio (ICER) of adding-on each new antiepileptic drug was calculated in terms of Rials per consequence (Rls/consq) and compared with each other. Furthermore ICER of the regimens was compared with the GDP per capita (Gross Domestic Product) of the year (2010).the ICER of the adding-on regimens range from negative values for Gabapentin, Levetiracetam and Zonisamide to low values for Lamotrigine (~ 6.4 million Rials/consequence [mil Rls/consq]) and Oxcarbazepine (~7.7 mil Rls/consq) and followed by high values for Topiramate (~21 mil Rls/consq) and Vigabatrin (~43.7 mil Rls/consq) considering the three months of remaining on regimen. By increasing the limit of remaining time to six months, the previously mentioned regimens persist on negative values. However Oxcarbazepine (~28.7 mil Rls/consq) and Lamotrigine (~13.8 mil Rls/consq) show a steep increase. Topiramate (~23.6 mil Rls/consq) displays a less change. Opposite to other regimens, the ICER value of Vigabatrin (~17.26 mil Rls/consq) has shown an important increase.Adding-on new antiepileptics to conventional regimens are cost-effective and justified considering the GDP per capita.Epilepsy is defined as a neurological disorder of brain portrayed by persisting predisposition to develop epileptic seizures [1]. A proportion of 6 over 1,000 children around the world are estimated to suffer from epilepsy and its psychological, social and intellectual development consequences [2]. Known as one of the most common neurological disorders worldwide, epilepsy has several treatment options. However pharmacotherapy remains the main
%K Cost-effectiveness
%K New antiepiletics
%K Intractable seizures
%K Children
%K Incremental cost-effectiveness ratio
%U http://www.darujps.com/content/20/1/17